Trends and associated factors in place of death among individuals with cardiovascular disease in China, 2008-2020: A population-based study

Wei Wang(National Center for Chronic and Noncommunicable Disease Control and Prevention), Maigeng Zhou(National Center for Chronic and Noncommunicable Disease Control and Prevention), Yong Huo(Sun Yat-sen University), Pengpeng Ye(University of Washington), Jinlei Qi(National Center for Chronic and Noncommunicable Disease Control and Prevention), Lin Lin(Fujian Business University), Jinling You(National Center for Chronic and Noncommunicable Disease Control and Prevention), Feixue Wang(National Center for Chronic and Noncommunicable Disease Control and Prevention), Peng Yin(National Center for Chronic and Noncommunicable Disease Control and Prevention), Yunning Liu(National Center for Chronic and Noncommunicable Disease Control and Prevention), Lijun Wang(National Center for Chronic and Noncommunicable Disease Control and Prevention), Jiangmei Liu(Chinese Center For Disease Control and Prevention)
The Lancet Regional Health - Western Pacific
February 2, 2022
10.1016/j.lanwpc.2022.100383
Cited by 28

Related Papers

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|6.5k
Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|3.8k
Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|1.5k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k